GT Biopharma (GTBP) Interest & Investment Income (2021 - 2026)

GT Biopharma (GTBP) has reported Interest & Investment Income for 5 consecutive years, with $67000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 109.38% year-over-year to $67000.0 in Q1 2026; TTM through Mar 2026 was $158000.0, a 45.89% decrease from a year earlier, with the FY2025 full-year figure at $123000.0, down 69.4% from the prior year.
• Interest & Investment Income was $67000.0 for Q1 2026 at GT Biopharma, up from $17000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $220000.0 in Q4 2023 and troughed at $17000.0 in Q4 2025.
• A 4-year average of $99333.3 and a median of $81500.0 in 2024 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income sank 77.46% in 2025 and jumped 109.38% in 2026, its largest moves.
• Over 4 years, Interest & Investment Income stood at $220000.0 in 2023, then tumbled by 73.18% to $59000.0 in 2024, then tumbled by 71.19% to $17000.0 in 2025, then surged by 294.12% to $67000.0 in 2026.
• The last three Interest & Investment Income figures came in at $67000.0 (Q1 2026), $17000.0 (Q4 2025), and $36000.0 (Q3 2025), per Business Quant data.